CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 150 enrolled
Drug / intervention
IDP-122 Vehicle Lotion +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02785185
NCT02785185Phase 2Completed

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion (0.01% Halobetasol Propionate) to Ultravate® (Halobetasol Propionate) Cream, in the Treatment of Plaque Psoriasis

Bausch Health Americas, Inc.·interventional·Posted May 27, 2016·Updated Aug 27, 2020

In Brief

A Phase 2 clinical trial evaluating IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, and 2 other interventions for Psoriasis. Completed, enrolled 150 participants across 13 sites.

Detailed Summary

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 27, 2016
Enrollment StartJun 1, 2016
Primary CompletionDec 2, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.1 years ago

Interventions

IDP-122 Vehicle Lotiondrug

Vehicle

IDP-122 Vehicle Creamdrug

Vehicle

IDP-122 Lotiondrug

Lotion

Ultravate Creamdrug

Cream